Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

AnaptysBio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, MAY 12, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A COMPANY FOCUSED ON MANAGING THE FINANCIAL COLLABORATIONS FORJEMPERLIWITH GSK AND IMSIDOLIMAB WITH VANDA, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

ANAPTYS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, MAY 11, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A COMPANY FOCUSED ON MANAGING THE FINANCIAL COLLABORATIONS FOR JEMPERLI WITH GSK AND IMSIDOLIMAB WITH VANDA, TODAY ANNOUNCED THE APPOINTMENT OF CHRISTOPHER MURPHY AS CHIEF FINANCIAL OFFICER AND OWEN HUGHES AS A MEMBER OF ITS BOARD OF DIRECTORS.

ANAPTYS APPOINTS CHRIS MURPHY AS CHIEF FINANCIAL OFFICER AND OWEN HUGHES TO BOARD OF DIRECTORS

SAN DIEGO, MAY 04, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A COMPANY FOCUSED ON MANAGING THE FINANCIAL COLLABORATIONS FORJEMPERLI WITH GSK AND IMSIDOLIMAB WITH VANDA, TODAY ANNOUNCED THAT DANIEL FAGA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ANAPTYS, IS SCHEDULED TO PARTICIPATE IN A FIRESIDE CHAT AT THE H.C. WAINWRIGHT 2ND ANNUAL ROYALTY COMPANY VIRTUAL CONFERENCE ON WEDNESDAY, MAY 6, 2026. THE FIRESIDE CHAT IS SCHEDULED TO BEGIN AT 1:30PM ET.

ANAPTYS TO PARTICIPATE AT THE H.C. WAINWRIGHT 2ND ANNUAL ROYALTY COMPANY VIRTUAL CONFERENCE

WASHINGTON, APRIL 28, 2026 /PRNEWSWIRE/ -- VANDA PHARMACEUTICALS INC. (VANDA) (NASDAQ: VNDA) TODAY ANNOUNCED THE PUBLICATION OF THE ORIGINAL RESEARCH ARTICLE TITLED "EFFICACY AND SAFETY OF IMSIDOLIMAB FOR GENERALIZED PUSTULAR PSORIASIS" IN NEW ENGLAND JOURNAL OF MEDICINE (NEJM) EVIDENCE1. THE FINDINGS OF THIS PIVOTAL PHASE III STUDY ARE INCLUDED IN THE BIOLOGICS LICENSE APPLICATION (BLA) FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS (GPP), SUBMITTED TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) WITH A TARGET ACTION DATE OF DECEMBER 12, 2026.

VANDA PHARMACEUTICALS ANNOUNCES THE PUBLICATION OF "EFFICACY AND SAFETY OF IMSIDOLIMAB FOR GENERALIZED PUSTULAR PSORIASIS" IN NEJM EVIDENCE

SAN DIEGO, APRIL 24, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A COMPANY FOCUSED ON MANAGING THE FINANCIAL COLLABORATIONS FOR JEMPERLI WITH GSK AND IMSIDOLIMAB WITH VANDA, TODAY ANNOUNCED THAT THE DELAWARE CHANCERY COURT HAS DISMISSED TESARO'S ANTICIPATORY BREACH OF CONTRACT CLAIM AGAINST ANAPTYS. THE RULING AGREES WITH ANAPTYS' POSITION THAT IT HAS NEVER REPUDIATED THE COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (COLLABORATION AGREEMENT) WITH TESARO, A SUBSIDIARY OF GSK, GOVERNING THE DEVELOPMENT AND COMMERCIALIZATION OF JEMPERLI.

DELAWARE CHANCERY COURT RULES IN FAVOR OF ANAPTYS BY DISMISSING TESARO'S ANTICIPATORY BREACH CLAIM

SAN DIEGO, APRIL 20, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A ROYALTY MANAGEMENT COMPANY, TODAY ANNOUNCED THE COMPLETION OF ITS SPIN-OFF OF FIRST TRACKS BIOTHERAPEUTICS, INC., ITS FORMER BIOPHARMA OPERATIONS BUSINESS.

ANAPTYS COMPLETES SEPARATION OF FIRST TRACKS BIOTHERAPEUTICS AND NOW EXCLUSIVELY MANAGES GSK AND VANDA FINANCIAL COLLABORATIONS

SAN DIEGO, MARCH 27, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB) TODAY ANNOUNCED THAT ITS PLANNED SPIN-OFF, FIRST TRACKS BIOTHERAPEUTICS, INC. (FIRST TRACKS BIO), AND ECOR1 CAPITAL (THE SELLING STOCKHOLDER) HAVE ENTERED INTO A PURCHASE AGREEMENT WITH CERTAIN THIRD-PARTY INVESTORS FOR A $145 MILLION PRIVATE PLACEMENT, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER EXPENSES.

FIRST TRACKS BIOTHERAPEUTICS, THE PLANNED SPIN-OFF OF ANAPTYS, SECURES COMMITMENTS OF $145 MILLION IN PRIVATE PLACEMENT

SAN DIEGO, MARCH 27, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED THE PREVIOUSLY ANNOUNCED SPIN-OFF OF FIRST TRACKS BIOTHERAPEUTICS, INC. (FIRST TRACKS BIO). THE NEW COMPANY IS EXPECTED TO BEGIN REGULAR-WAY TRADING ON THE NASDAQ STOCK MARKET LLC (NASDAQ) ON APRIL 20, 2026, UNDER THE TICKER SYMBOL TRAX.

ANAPTYS BOARD OF DIRECTORS APPROVES SPIN-OFF OF FIRST TRACKS BIOTHERAPEUTICS

SAN DIEGO, MARCH 27, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED A STOCK REPURCHASE PLAN UNDER WHICH THE COMPANY MAY REPURCHASE UP TO $100,000,000 OF THE COMPANY'S OUTSTANDING COMMON STOCK, PAR VALUE $0.001 PER SHARE, AND PROVIDED A BUSINESS UPDATE.

ANAPTYS ANNOUNCES $100 MILLION STOCK REPURCHASE PLAN AND PROVIDES A BUSINESS UPDATE

SPIN-OFF OF BIOPHARMA OPERATIONS INTO A PUBLIC COMPANY TO BE CALLED FIRST TRACKS BIOTHERAPEUTICS ON TRACK FOR Q2 2026, POTENTIALLY AS EARLY AS LATE-APRIL PHASE 1B ENROLLMENT ONGOING IN CELIAC DISEASE AND TRIAL COHORT INITIATED IN EOSINOPHILIC ESOPHAGITIS FOR ANB033, A CD122 ANTAGONIST GSK ANNOUNCED STRONG COMMERCIAL PERFORMANCE FOR JEMPERLI, GROWING >13% QUARTER-OVER-QUARTER TO $343 MILLION IN Q4 2025, IMPLYING A ~$1.4 BILLION ANNUALIZED RUN RATE EXPECT TO ACHIEVE >$390 MILLION IN ANNUALIZED JEMPERLI ROYALTIES PAYABLE TO ANAPTYS AT GSK'S PEAK SALES GUIDANCE OF >$2.7 BILLION AS EARLY AS 2029 YEAR-END 2025 CASH AND INVESTMENTS OF ~$311 MILLION SAN DIEGO, MARCH 03, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY PROVIDED AN UPDATE ON THE POTENTIAL SPIN-OFF OF ITS BIOPHARMA OPERATIONS AND REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DEC. 31, 2025. WE ARE APPROACHING A DEFINING INFLECTION POINT FOR ANAPTYS, AS WE PLAN TO SPIN-OFF IN Q2 2026 OUR WHOLLY OWNED BIOPHARMA PORTFOLIO INTO A PUBLIC COMPANY, TO BE CALLED FIRST TRACKS BIOTHERAPEUTICS, TO UNLOCK AND AMPLIFY VALUE FOR INVESTORS ACROSS TWO DISTINCT SETS OF ASSETS, SAIDDANIEL FAGA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ANAPTYS.

AnaptysBio, Inc.

ANAB

Price

Financial Reports

No items found.

Press Releases

AnaptysBio, Inc.

ANAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ANAB